Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

May 14, 2024

https://www.globenewswire.com/news-release/2024/05/14/2881841/0/en/Allarity-Therapeutics-Reports-First-Quarter-Financial-Results-and-Highlights-including-Clear-Clinical-Benefits-from-Phase-2-Trial-NASDAQ-Compliance-and-Significant-Improvement-in-C.html

– Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved

– On Track to Regain Compliance with All Nasdaq Listing Requirements

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.